Tag-Assisted Peptide Synthesis (TAPS) – Development of an Efficient Liquid-Phase Process
Peptide synthesis has traditionally relied on Classic Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), each with inherent limitations. LPPS, while efficient in reagent use, is only suitable for short peptides and requires tedious isolation steps. SPPS, widely adopted, is solvent-intensive and presents challenges in large-scale manufacturing. TAG-Assisted Peptide Synthesis (TAPS) combines the best of both worlds, offering an innovative hybrid approach that integrates LPPS and SPPS advantages. This method employs a TAG-anchor molecule, which solubilizes the growing peptide in an organic solution, allowing for multiple elongation cycles without isolation, significantly improving efficiency. TAPS presents a highly efficient, sustainable, and scalable alternative to traditional peptide synthesis.
Corden Pharma International GmbH
-
Country/Region:Germany
-
On CPHI since:2015
-
Certificates:4
-
Employees:1000 - 4999
Other Content from Corden Pharma International GmbH (21)
-
News CordenPharma Expands Early Clinical Peptide Manufacturing to Launch IND-Targeted Peptide API to Injectable Drug Product Integrated Offer
After an initial expansion of the CordenPharma Frankfurt site for non-GMP manufacturing in 2020, and because of sustained success and exemplary performance delivered by their expert team, CordenPharma is pleased to announce the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers. The investment, which is still being finalized, will be fully operational in Q2 2024 and authorized by German authorities in H2 2024. -
News CordenPharma & GENEPEP Celebrate Strong Collaboration Leveraging Peptide Drug Substance Discovery & Clinical Development Expertise
CordenPharma, a global CDMO leader in the manufacturing of Drug Substance (APIs) complex modalities (such as peptides, oligos and lipids) and injectable Drug Products, and GENEPEP, a French CRO specializing in the design, chemical synthesis, and optimization of peptides, peptide libraries and proteins, have celebrated one year of their fruitful collaboration.
-
News CordenPharma & Certest: A Powerful Partnership Unleashing the Potential of Patented Ionizable Lipids in LNP Formulation Press Releases 06 Jun 24
CordenPharma, a global CDMO leader in the manufacture of Drug Substances (APIs) for complex modalities (such as peptides, GalNAc, lipids, etc.), Lipid NanoParticles (LNPs) containing xRNA / xDNA, and injectable Drug Products, and Certest, a Spanish company focused on the development of new products with special emphasis in Drug Delivery with LNPs and API synthesis, have signed a partnership agreement. -
News WACKER & CordenPharma Enter Pandemic Readiness on 1 June 2024 After Successful Expansion & Qualification
Consortium formed between WACKER & CordenPharma has officially entered the pandemic readiness state as of 1 June 2024 to produce 80 million vaccine doses within a short time, if needed. Following a successful expansion and qualification phase, the companies are now in a stand-by readiness phase for at least five years. Should the need arise, the German government will contact the developer of the specific mRNA vaccine required and WACKER & CordenPharma will then jointly produce this mRNA vaccine in line with the highest pharmaceutical quality standards.
-
News CordenPharma Receives SBTi Approval for Near-Term Science-Based Greenhouse Gas Emission Reduction Targets
Basel, Switzerland – 6 May 2025 > CordenPharma is proud to announce that the Science-Based Targets initiative (SBTi) has officially approved the group’s near-term greenhouse gas (GHG) emission reduction targets. Following a two-year carbon footprint measurement process resulting in a submission of the targets in November 2024, the SBTi’s Target Validation Team has confirmed that the group’s ambition is in conformance with the SBTi Standards and Guidance. -
News CordenPharma submits greenhouse gas emission reduction targets to SBTi
CordenPharma has submitted its near-term greenhouse gas (GHG) emission reduction targets to the Science Based Targets initiative (SBTi) for approval, marking a major step in its climate action commitments.
-
News CordenPharma signs billion dollar agreement to manufacture new peptide
CordenPharma, the CDMO specialising in APIs, lipid excipients, and drug products, signs a new billion dollar contract to expand its manufacturing capabilities.
-
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming.
-
News CPHI Frankfurt 2022: Innovator Interview – CordenPharma
In this interview from CPHI Frankfurt 2022, we speak to Dr Michael Quirmbach of CordenPharma about his role as President and CEO and what CordenPharma is bringing to the pharma industry.
-
News Press Release > CordenPharma Colorado Expands Lipid Excipients Purification
Luxembourg, 19 April 2021 -- In response to the COVID-19 pandemic, mRNA (messenger RNA) vaccines have catapulted to center stage of the pharmaceutical and biotechnology industry. As of early 2021, there are eight ongoing human trials for mRNA vaccines led by Moderna, BioNTech / Pfizer, CureVac, Sanofi / TranslateBio, Arcturus / Duke-NUS Medical School (Singapore), Imperial College London, Chulalongkorn University (Thailand), and Providence Therapeutics.
